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What is already known about the topic? Evidence on the impact of use of hormonal replacement therapy (HRT) on
clinical outcomes of asthma in perimenopausal and postmenopausal women with asthma is lacking.
What does this article add to our knowledge? Use of HRT in the long term may increase the risk of severe asthma
exacerbation in perimenopausal and postmenopausal women.
How does this study impact current management guidelines? Although current findings do not suggest changes in
management of asthma in perimenopausal and postmenopausal women, studies uncovering the mechanisms through
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BSO- Bilateral salpingo-oophorectomy
CI- Confidence intervalCOPD- Chronic obstructive pulmonary disease
ER- Estrogen receptorHRT- Hormonal replacement therapy
IMD- Index of multiple deprivationOPCRD-Optimum Patient Care Research Database
QOF- Quality and Outcomes FrameworkRECORD- Reporting of studies Conducted using Observational
Routinely-collected DataSTROBE- Strengthening the Reporting of Observational Studies in
EpidemiologyBACKGROUND: The impact of hormone replacement therapy
(HRT) on clinical outcomes in menopausal women is uncertain.
OBJECTIVE: To investigate the association between use of HRT
and severe asthma exacerbation in perimenopausal and
postmenopausal women with asthma.
METHODS: We used the Optimum Patient Care Research
Database, a population-based longitudinal primary care data-
base in the United Kingdom, to construct a 17-year (January 1,
2000, to December 31, 2016) cohort of perimenopausal and
postmenopausal (46-70 years, N [ 31,656) women. We defined
use of HRT, its subtypes, and duration of HRT use. Severe
asthma exacerbation was defined as an asthma-related hospital-
ization, emergency department visits due to asthma, and/or
prescription of oral corticosteroids. Analyses were undertaken
using multilevel mixed-effects Poisson regression.
RESULTS: At baseline, 22% of women were using any HRT,
11% combined HRT, and 11% estrogen-only HRT. Previous,
but not current, use of any (incidence rate ratio [IRR]: 1.24, 95%
confidence interval [CI]: 1.22-1.26), combined (IRR: 1.28, 95%
CI: 1.25-1.31), and estrogen-only HRT (IRR: 1.18, 95% CI:
1.14-1.21), and longer duration (1-2 years: IRR: 1.16, 95% CI:
1.13-1.19; 3-4 years: IRR: 1.43, 95% CI: 1.38-1.48; 5D years:
IRR: 1.32, 95% CI: 1.28-1.36) of HRT use were associated with
increased risk of severe asthma exacerbation compared with
nonuse. The risk estimates were greater among lean women
(body mass index [BMI] <25 kg/m2) than among heavier women
(BMI 25-29.9 kg/m2 and ‡30 kg/m2) and higher among smokers
than nonsmokers.
CONCLUSION: Use of HRT and subtypes, particularly
previous, but not current, use and use for more than 2 years, is
associated with an increased risk of severe asthma exacerbation
in perimenopausal/postmenopausal women with established
asthma. Lean women and smokers are at greater risk than
heavier women and nonsmokers, respectively.  2021 The
Authors. Published by Elsevier Inc. on behalf of the American
Academy of Allergy, Asthma & Immunology. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/). (J Allergy Clin Immunol Pract
2021;9:2751-60)
Key words: Asthma exacerbation; Combined hormone therapy;
Estrogen-only therapy; Hormone replacement therapy; Meno-
pause; Women; Cohort study
Hormone replacement therapy (HRT), an umbrella term used
for both estrogen-only and combined estrogen-progestogenhormone treatments, has long been used to mitigate the symp-
toms caused by menopause, a period of decline in the production
of endogenous estrogen and progesterone hormones in peri-
menopausal and postmenopausal women.1 Given the sex-related
differences in asthma pathogenesis and clinical manifestation,
largely attributed to the role of sex steroid hormones,2-4 HRT has
long been suspected to play a role in asthma in women.5 For
several decades, several studies have attempted to address this
question, but the underlying evidence base is uncertain as find-
ings from previous studies are conflicting.6 Findings from our
recent systematic review and meta-analysis showed that to date,
there are no prospective cohort studies investigating the impact
of use of HRT on clinical outcomes of asthma in perimenopausal
and postmenopausal women with established asthma.6 Previous
studies, which have been cross-sectional and retrospective case-
control studies, are hampered by their inability to establish
temporality of association between HRT and clinical outcomes
of asthma, self-selection bias, and ascertainment bias.6 To over-
come these limitations, there is a need to undertake long-term
longitudinal cohort studies to investigate and clarify the impact
of use of HRT on subsequent clinical outcomes of asthma in
perimenopausal and postmenopausal women with established
asthma.
The aim of the current study was to investigate the association
of use of HRT, its subtypes, and duration of use with severe
asthma exacerbation in perimenopausal and postmenopausal
women with asthma. We also examined whether body mass
index (BMI), cigarette smoking, and menopausal status (peri-
and postmenopause) modified these associations.
METHODS
Ethics approvals and permissions
The Anonymised Data Ethics and Protocol Transparency Com-
mittee, responsible for approval of research using the Optimum
Patient Care Research Database (OPCRD), gave approval for the
current study (reference number: ADEPT1317). In addition, Op-
timum Patient Care has an existing ethics approval for the use of
OPCRD for research purposes from the NHS Health Research
Authority (REC Ref: 15/EM/150). All researchers involved in data
analysis completed required information governance courses.
Protocol registration and publication
The study protocol was registered with the European Union
electronic Register of Post-Authorization Studies (EUPAS22967)
and also published in a peer-reviewed journal before the analyses
were undertaken.7
Study design and population
OPCRD is a longitudinal anonymized primary care database,
comprising 630 primary care practices across the United Kingdom
with more than 6 million patients at the time of extracting data for
the current study. The database is used to conduct epidemiological,
clinical, and pharmaceutical studies (http://optimumpatientcare.org/
opcrd/).8,9 We established an open (meaning that cohort members
can enter or leave the cohort anytime during follow-up) retrospective
cohort of perimenopausal and postmenopausal women (46-70 years)
who had any asthma event (including diagnosis, hospitalization,
medication prescription) using previously established Read codes
(available in this article’s Online Repository at www.jaci-inpractice.
org) starting from baseline on January 1, 2000. Participants
entered the cohort from baseline or date of registration to a general
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until December 31, 2016. Participants exited the cohort on the date
of death, deregistration from a practice, year of turning 70 years, or
December 31, 2016, whichever came first. In total, 31,656 peri-
menopausal and postmenopausal women were included in the study
(Figure 1).
Ascertainment of hormonal contraceptives and HRT
We used the Read Clinical Classification System10 (Read codes,
available in this article’s Online Repository at www.jaci-inpractice.
org) to extract information on prescription of HRT. On the basis
of the extracted information, we defined the following exposure
categories for the use of HRT for each year of follow-up:
1. Previous (anytime in the past) and current (during that year) use
versus nonuse
2. Previous and current use of subtypes of HRT (combined estro-
gen/progestogen, estrogen-only)
3. Duration of use: 1-2 years, 3-4 years, 5 years, or more versus
nonuse.
Patients’ use of HRT was individually ascertained for every year.
In cases where a patient experienced severe asthma exacerbation,
HRT use was only counted if the prescription for HRT preceded the
asthma exacerbation event in that year.
Potential confounding variables
We selected potential confounding factors based on evidence
from previous literature and demonstrated these using a directed
acyclic graph (Figure E1, available in this article’s Online Repository
at www.jaci-inpractice.org). Using relevant Read codes (available in
this article’s Online Repository at www.jaci-inpractice.org), we
extracted information from the database and defined the following
variables: gravidity, BMI, smoking, Charlson comorbidity index,11
gynecological conditions that are potentially subject to hormonal
manipulation—either through supplementation or inhibition—and
those that potentially result from estrogen deficiency (endometriosis,
polycystic ovary syndrome, acne, bilateral salpingo-oophorectomy
[BSO], hysterectomy with BSO, hysterectomy without BSO, fi-
broids, and menstrual bleeding complaints identified under coding
terms: menorrhagia, metrorrhagia; menometrorrhagia),12 and index
of multiple deprivation (IMD).13 The IMD is a multidimensional
measure used to categorize neighborhoods across the United
Kingdom on the basis of material living conditions to determine
resource allocation and service provision. Thus, although the IMD
provides information on neighborhood relative deprivation, it gives
an indirect indication of socioeconomic status of the neighbor-
hood.13 Age was derived using the date of birth. Baseline asthma
severity was classified based on the Global Initiative for Asthma
severity steps.
Study outcome
Our study outcome was the occurrence of severe asthma exacer-
bation (Read codes, available in this article’s Online Repository at
www.jaci-inpractice.org), which was defined according to the
recommendation of the European Respiratory Society/American
Thoracic Society14 as asthma-related hospitalization, emergency
department visits due to asthma, and/or prescription of oral corti-
costeroids. We counted the yearly number of asthma exacerbations,
measured longitudinally during the 17-year follow-up on each pa-
tient. We considered severe asthma exacerbation occurring within a14-day period as 1 event. This definition has been validated and used
in previous studies using the OPCRD database.15
Statistical analyses
We used Pearson’s c2 test to describe the distribution of the
baseline study characteristics in relation to the use of HRT and se-
vere asthma exacerbation (Table I). To study the association between
HRT use and severe asthma exacerbation, we used multilevel mixed-
effects Poisson regression. As the mean number of annual severe
asthma exacerbation (0.26) and its variance (0.52) were not exactly
the same, we initially implemented multilevel mixed-effects negative
binomial regression to the data, but the models did not converge.
For this reason, we used multilevel mixed-effects Poisson regression
with QR decomposition, which provides an alternative to fitting
models for Poisson distributed data. By using the QR decomposition
of the variance-components matrix, this analysis approach aids
improvement of the convergence of models when the variance
components is close to the border of the parameter space.16 In
estimating the association between HRT and severe asthma exacer-
bation (but not in the descriptive analyses), women who experienced
any asthma exacerbation at baseline (prevalent cases, n ¼ 5172; see
Figure 1 and Table I) were excluded from the analysis, allowing us to
estimate a temporal association between baseline HRT and post-
baseline severe asthma exacerbation (ie, new severe asthma exacer-
bation). The models, while accounting for variations across general
practices, also took into account the nesting of patients within
general practices; that is, the models included random effects for
both patients and practices. Furthermore, the models accounted for
the longitudinal nature of the data, so that each variable was allowed
to take different values at each year of follow-up. We adjusted for the
above-described potential confounding variables, which were
included in the models using the categories given in Table I. In-
teractions of BMI and smoking with HRT were examined by
including interaction terms in each adjusted model; the analyses
were subsequently stratified by BMI or smoking if the interaction
terms achieved P values of <.20. The analyses were in addition
stratified by menopausal status (peri- and postmenopausal women).
We evaluated the potential for residual confounding after the
adjusted regression analyses by calculating the E values for the
observed estimates of association between HRT use and severe
asthma exacerbation.17 The estimates of the E value indicate the
minimum magnitude of association that an unmeasured confounder
should have in relation to both respective exposures and outcome in
order to negate the observed estimate of association between the
respective exposures and the outcome.17 Data management and
editing were undertaken using R version 3.5.1 (R Foundation for
Statistical Computing, Vienna, Austria). Statistical analyses were
undertaken using and Stata 14 (Stata Statistical Software: Release 14;
StataCorp LP, College Station, Tex).
Reporting
We followed the recommendations of STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology)18 and
RECORD (Reporting of studies Conducted using Observational
Routinely-collected Data)19 in reporting the study results.
RESULTS
Characteristics of the study populations
The 17-year follow-up of the 31,656 women amounted to
366,678 person-years of follow-up time (Figure 1). At baseline
(ie, the year a woman joined the study cohort), 22% of women
FIGURE 1. Flowchart of study cohort and baseline severe asthma exacerbation and HRTuse. HRT, Hormone replacement therapy.
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only HRT. Use of any HRT, combined estrogen/progestogen
HRT, and estrogen-only HRT was highest among women 51 to
55 years of age and then decreased afterward; higher in ex-/
current smokers than nonsmokers; higher in those with BMI
<25 kg/m2 than in those with greater BMI; higher in women
who had never been pregnant than those who had been; less in
women with a comorbidity score of 1 to 3 than those with lower
and higher scores; and relatively equally distributed between
IMD quintiles (Table I). Use of any HRT and estrogen-only
HRT was higher in women with a prior gynecological condi-
tion (ie, situations resulting in estrogen deficiency: BSO, hys-
terectomy with BSO; and also, management of perimenopausal
menstrual bleeding complaints) than those without, but use of
combined estrogen/progestogen HRT was higher in those
without a prior gynecological condition than those with. Use of
any HRT and combined estrogen/progestogen HRT was morecommon among perimenopausal women than among post-
menopausal women, whereas use of combined estrogen-only
HRT was more common among postmenopausal women than
among perimenopausal women.
A total of 5172 (16%) of the women had experienced severe
asthma exacerbation at baseline (Figure 1 and Table I). The
annual mean number of severe asthma exacerbation at baseline
was 0.26 (standard deviation, 0.71). Severe asthma exacerbation
at baseline was highest in women aged 46 to 50 years than in
other age groups; higher in ex-/current smokers than in non-
smokers; highest in obese than in nonobese women; highest in
women who had 3 or more pregnancies than women who had
fewer pregnancies; higher in women with a prior gynecological
condition than those without; highest in women with a co-
morbidity score of 4 and above than those with lower scores;
higher in peri- than in postmenopausal women; and relatively
equally distributed between IMD quintiles and between baseline
TABLE I. Baseline characteristics by use of hormone replacement therapy (HRT) and severe asthma exacerbation at baseline
Baseline characteristics
Frequency




No HRT use n [ 24,554
(77.6%) n (%)
Used combined HRT
n [ 3472 (11%) n (%)
Used estrogen-only HRT
n [ 3589 (11.3%) n (%)






n [ 5172 (16%)
n (%)
Age (y)
46-50 14,677 (46.4) 2875 (19.6) 11,802 (80.4) 1649 (11.2) 1226 (8.3) 0.29 (0.75) 2763 (18.8)
51-55 6087 (19.2) 1818 (29.9) 4269 (70.1) 872 (14.3) 946 (15.5) 0.22 (0.66) 840 (13.8)
56-60 4722 (14.9) 1290 (27.3) 3432 (72.7) 558 (11.8) 732 (15.5) 0.24 (0.74) 679 (14.4)
61-65 3599 (11.4) 745 (20.7) 2854 (79.3) 278 (7.7) 467 (13.0) 0.22 (0,66) 508 (14.1)
66-70 2571 (8.1) 333 (12.9) 2238 (87.0) 115 (4.5) 218 (8.5) 0.23 (0.69) 382 (14.9)
Smoking status
Nonsmoker 13,395 (42.3) 2701 (20.2) 10,694 (79.8) 1321 (9.9) 1380 (10.30) 0.21 (0.63) 1875 (14.0)
Ex-/current smoker 18,261 (57.7) 4360 (23.9) 13,901 (76.1) 2151 (11.8) 2209 (12.1) 0.29 (0.78) 3297 (18.0)
Body mass index (kg/m2)
<25 9210 (29.1) 2323 (25.2) 6887 (74.8) 1246 (13.5) 1077 (11.7) 0.22 (0.67) 1311 (14.2)
25-29.9 10,265 (32.4) 2410 (23.5) 7855 (76.5) 1102 (10.7) 1308 (12.7) 0.23 (0.67) 1517 (14.8)
30 12,181 (38.5) 2328 (19.1) 9853 (80.9) 1124 (9.2) 1204 (9.9) 0.31 (0.79) 2344 (19.2)
Gravidity
None 19,805 (62.6) 4665 (23.5) 15,140 (76.4) 2290 (11.6) 2375 (12.0) 0.23 (0.69) 2891 (14.6)
One 4219 (13.3) 843 (20.0) 3376 (80.0) 412 (9.8) 431 (10.2) 0.29 (0.73) 794 (18.8)
Two 4142 (13.1) 842 (20.3) 3300 (79.7) 418 (10.1) 424 (10.2) 0.28 (0.73) 752 (18.2)
Three or more 3490 (11.0) 711 (20.4) 2779 (79.6) 352 (10.1) 359 (10.3) 0.34 (0.82) 735 (21.1)
Any gynecological condition*
No 12,049 (38.1) 2323 (19.3) 9726 (80.7) 1612 (13.4) 711 (5.9) 0.22 (0.69) 1671 (13.9)
Yes 19,607 (61.9) 4738 (24.2) 14,869 (75.8) 1860 (9.5) 2878 (14.7) 0.28 (0.73) 3501 (17.9)
Charlson comorbidity index
0 24,592 (77.7) 5653 (23.0) 18,939 (77.0) 2871 (11.7) 2782 (11.3) 0.23 (0.66) 3658 (14.9)
1-3 1189 (3.8) 201 (16.90) 988 (83.1) 87 (7.3) 114 (9.6) 0.31 (0.81) 230 (19.3)
4þ 5875 (18.6) 1207 (20.5) 4668 (79.5) 514 (8.7) 693 (11.8) 0.37 (0.89) 1284 (21.9)
Index of multiple deprivation quintiles
1st quintile (least deprived) 6126 (19.3) 1299 (21.2) 4827 (78.8) 667 (10.9) 632 (10.3) 0.26 (0.73) 1006 (16.4)
2nd quintile 5688 (18.0) 1132 (19.9) 4556 (80.1) 533 (9.4) 599 (10.5) 0.28 (0.77) 975 (17.1)
3rd quintile 6259 (19.8) 1507 (24.1) 4752 (75.9) 727 (11.6) 780 (12.5) 0.24 (0.66) 986 (15.7)
4th quintile 7060 (22.3) 1665 (23.6) 5395 (76.4) 817 (11.6) 848 (12.0) 0.25 (0.71) 1162 (16.5)
5th quintile (most deprived) 6523 (20.6) 1458 (22.3) 5065 (77.6) 728 (11.2) 730 (11.2) 0.25 (0.72) 1043 (16.0)
Menopausal status
Perimenopause 18,366 (58.0) 4243 (23.1) 14,123 (76.9) 2413 (13.1) 1830 (10.0) 0.27 (0.73) 3230 (17.6)
Postmenopause 13,290 (42.0) 2818 (21.2) 10,472 (78.8) 1059 (8.0) 1759 (13.2) 0.23 (0.69) 1942 (14.6)
Used any HRT at baseline e e e e
No 24,595 (77.7) 0.25 (0.71) 4017 (16.3)
Yes 7061 (22.3) 0.26 (0.75) 1155 (16.4)
*Defined as having any of the following conditions: endometriosis, polycystic ovary syndrome, menorrhagia, acne, metrorrhagia, bilateral salpingo-oophorectomy (BSO), hysterectomy BSO, hysterectomy, fibroids, and menometrorrhagia.
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exacerbation was 11%, 13%, and 19% in women with the BMI
of <25, 25 to 29.9, and 30 kg/m2, respectively, among women
who had not experienced any severe asthma exacerbation at
baseline (data not shown).
Association between use of HRT and severe asthma
exacerbation
Previous use of any HRT, combined estrogen/progestogen
HRT, and estrogen-only HRT, compared with nonuse, was
associated with an increased risk of severe asthma exacerbation
(Figure 2). Whereas the current use of any HRT, compared with
nonuse, was associated with a small increased risk of severe
asthma exacerbation, the current use of combined estrogen/
progestogen and estrogen-only HRT was not significantly asso-
ciated with severe asthma exacerbation. Compared with non-
HRT use, any duration of use was associated with an increased
risk of exacerbation (Figure 2), but the risk was lowest for 1 to 2
years of use and highest for 3 to 4 years of use. Although the
results were not substantially different between perimenopausal
and postmenopausal women, previous use of estrogen-only HRT
was associated with up to 24% (95% confidence interval [CI]:
16-29) but only 7% (95% CI: 3-12) increased risk of severe
asthma exacerbation in perimenopausal and postmenopausal
women, respectively (Figure 3). The estimated E values for the
association between use of any HRT and severe asthma exacer-
bation ranged from 1.00 (for the current use of any HRT) to
2.21 (for 3-4 years of use of HRT), signifying that an unmea-
sured confounder requires a minimum risk ratio of 1.00 and a
maximum of 2.21 to negate the observed association between
HRT and severe asthma exacerbation after adjusting for all other
confounding factors (data not shown). The least E values were
observed for current HRT use and subtypes, indicating that
whereas these results may be influenced by residual confounding,
the results for previous HRT use and duration of HRT are less
likely to be negated by residual confounding.
In stratified analyses by BMI, although there was an increased
risk of severe asthma exacerbation with HRT use across the BMI
groups, in most cases, the risk estimates were highest for women
with BMI <25 kg/m2, followed by those for women with BMI
25 to 29.9 kg/m2, and less in obese women (BMI 30 kg/m2)
(Table II). In the stratified analyses by smoking status, only
previous and current use of any HRT and estrogen-only HRT,
but not combined estrogen/progestogen and duration of HRT
use, were associated with an increased risk of severe asthma
exacerbation among nonsmokers. However, among ex-/current
smokers, use of any HRT, combined estrogen/progestogen, and
estrogen-only HRT, previously and currently, and long-term
HRT use, was clearly associated with an increased risk of se-
vere asthma exacerbation (Table II).
DISCUSSION
In this national longitudinal cohort of perimenopausal and
postmenopausal women with asthma who were followed for 17
years, we found that previous but not current use of any HRT,
combined estrogen/progestogen HRT, and estrogen-only HRT
and long-term use was associated with an increased risk of severe
asthma exacerbation. These results were overall similar for peri-
and postmenopausal women, but the risk estimates were greater
for lean women than heavier women and greater for smokers
than nonsmokers. Sensitivity analyses examining the impact ofresidual confounding on these results showed that, whereas the
observations made with regard to current HRT use may be
influenced by residual confounding, the results regarding previ-
ous and duration of HRT use were generally unlikely to be
influenced of residual confounding.
OPCRD is one of the leading primary care databases in the
United Kingdom dedicated to clinical and pharmacoepidemio-
logic studies with a well-characterized patient cohort that is
largely representative of the UK primary care population. At the
time of undertaking the current study, there were 6.3 million
patients in the OPCRD database covering 630 general practices
from across the United Kingdom. With the large sample size in
the current study, we could address the question of the impact of
HRT on severe asthma exacerbation by considering the role of
both duration and subtypes of HRT, thus providing precise es-
timates of effect sizes of the associations. With a 17-year follow-
up and in a longitudinal perspective, we were able to study the
long-term impact of HRT on severe asthma exacerbation. The
longitudinal framework also allowed us the opportunity to
evaluate the time dependence of the impact of HRT on the
outcome. On the basis of this, our analysis took into account the
possibility that participants’ use of HRT could change over
the study follow-up period. Therefore, participants’ HRT use
status changed from nonusers in the years they did not use HRT
to users in the years they used HRT. Given the challenge of
immortal time bias, a common bias in pharmacoepidemiologic
studies evaluating the effect of medical therapies on disease
outcomes, the approach of allowing time dependences in the use
of HRT is useful in minimizing the impact of immortal time
bias.20 All study variables were defined using the Read Clinical
Classification System, which is a standardized system for doc-
umenting primary care events in the United Kingdom, thereby
ensuring consistent recording of the study variables.10
Although it may be considered that the Quality and Out-
comes Framework (QOF), a national initiative established in
2004 incentivizing primary care centers to maintain a register of
patients with asthma for improvements in recording of clinical
events, may have led to differential diagnosis of asthma during
the study follow-up, 13 of the 17 years of follow-up of our study
occurred after adoption of QOF.21 Therefore, given that the
majority of the study period occurred during the QOF pro-
gram, any bias due to underdiagnosis of asthma would have
been minimal. We defined severe asthma exacerbation after
recommendation of the European Respiratory Society/Amer-
ican Thoracic Society,14 and this definition has been previously
defined within the OPCRD database.15 However, provision of
asthma action plans with oral corticosteroid scripts may possibly
lead to overestimates in those having 1 severe asthma exacer-
bation. There is a possibility that some asthma cases might have
been a result of misdiagnosis of chronic obstructive pulmonary
disease (COPD). However, the Read codes we used for defining
asthma have been previously validated in another comparable
general practitioner database, which resulted in high accuracy.22
Moreover, the concomitance between asthma and COPD based
on Read codes has been estimated to be less than 15%.23
Therefore, any potential misclassification of asthma in study
as COPD will be minimal and is unlikely to change our con-
clusions from our study. Several other conditions, for example,
endometriosis and fibroids, may be subject to hormonal
manipulation—either through supplementation or inhibition—
or may potentially result from estrogen deficiency, and thus may
FIGURE 2. Unadjusted and adjusted associations between use of hormone replacement therapy (HRT) and severe asthma exacerbation in
all women. Women with severe asthma exacerbation at baseline were excluded in these analyses to estimate the impact of HRTon new
asthma exacerbation. CI, Confidence interval.
FIGURE 3. Adjusted associations between use of hormone replacement therapy (HRT) and severe asthma exacerbation by menopausal
status. Womenwith severe asthma exacerbation at baseline (n ¼ 5172) were excluded in these analyses to estimate the impact of HRTon
new asthma exacerbation. CI, Confidence interval.
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identified a list of these conditions, including those that HRT
may be used as a therapy and adjusted for these in our analyses.
We defined perimenopausal and postmenopausal age, including
cutoff for peri- and postmenopausal women, based only on the
age of the women, because the age of menopause is not recorded
in the database as an event and there was no additional infor-
mation from the database to enhance these definitions. How-
ever, the chosen ages reflect the average ages of the menopausal
events in the United Kingdom. Information on HRT was based
only on medication prescription, and thus we could not
establish whether the women actually used the prescribed
medications, because we did not have information on medica-
tion dispensation.Before embarking on the data analysis, we registered the
analysis protocol for the current study, which was also published
in a peer-reviewed journal, providing details of our analysis
strategies.7 This ensured the transparency of the current work,
and any deviations from the protocol have been explained in the
current manuscript. Registering and publishing the protocol
before undertaking the analysis enhanced the transparency of our
work. The protocol included a plan for propensity score analysis
for adjusting for potential confounding factors,4 but this could
not be implemented as planned because we found no appropriate
algorithm for propensity score analyses for multilevel models
with time-varying covariates. In the absence of propensity score
analysis, we performed conventional confounder adjustment by
simultaneously adjusting for all the confounding factors in the
TABLE II. Association between use of hormone replacement therapy (HRT) and severe asthma exacerbation in perimenopausal and
menopausal women, stratified by BMI and smoking*
HRT use
Stratified analyses by BMI
Incidence rate ratio (95% CI)
†,z
Stratified analyses by smoking status
Hazard ratio (95% CI)
x,k
<25 kg/m2 25-29.9 kg/m2 ‡30 kg/m2 Nonsmokers Smokers
Previous use of any HRT
None 1 1 1 1 1
Yes 1.37 (1.32-1.42) 1.25 (1.21-1.30) 1.18 (1.15-1.22) 1.08 (1.04-1.11) 1.32 (1.29-1.35)
Current use of any HRT
None 1 1 1 1 1
Yes 1.20 (1.15-1.25) 1.11 (1.06-1.16) 0.98 (0.94-1.02) 1.13 (1.08-1.18) 1.10 (1.07-1.14)
Type of HRT (previous use)
None 1 1 1 1 1
Estrogen only 1.49 (1.41-1.58) 1.25 (1.18-1.32) 1.08 (1.03-1.14) 1.19 (1.13-1.26) 1.22 (1.17-1.26)
Combined estrogen/progestogen 1.34 (1.29-1.40) 1.25 (1.20-1.31) 1.34 (1.28-1.38) 1.03 (0.99-1.07) 1.43 (1.39-1.46)
Type of HRT (current use)
None 1 1 1 1 1
Estrogen only 1.34 (1.27-1.41) 1.16 (1.10-1.22) 1.01 (0.96-1.06) 1.19 (1.13-1.25) 1.08 (1.05-1.13)
Combined estrogen/progestogen 1.06 (1.00-1.12) 1.04 (0.97-1.11) 0.94 (0.88-1.00) 1.05 (0.98-1.12) 1.14 (1.09-1.18)
Duration of use of any HRT (y)
None 1 1 1 1 1
1-2 1.25 (1.20-1.31) 1.25 (1.20-1.30) 0.98 (0.95-1.01) 0.97 (0.94-1.01) 1.09 (1.07-1.12)
3-4 2.18 (2.06-2.30) 1.02 (0.96-1.08) 1.24 (1.19-1.29) 0.95 (0.91-1.00) 1.31 (1.27-1.36)
5þ 1.53 (1.44-1.62) 1.42 (1.34-1.49) 1.35 (1.30-1.41) 1.04 (0.99-1.10) 1.39 (1.34-1.43)
Bolded numbers indicate statistical significance at P < 0.05 threshold.
*All analyses were based on multilevel mixed-effects Poisson regression that accounted for clustering of patients within general practitioner practices. Women with severe
asthma exacerbation at baseline (n ¼ 5172) were excluded in these analyses to estimate the impact of HRT on new asthma exacerbation.
†Adjusted for asthma severity level at baseline, age, smoking, Charlson comorbidity index, gravidity, any gynecological condition, and index of multiple deprivation.
zStratified analyses performed after the interaction term between use of HRT and BMI gave P < .20.
xAdjusted for asthma severity level at baseline, age, Charlson comorbidity index, BMI, gravidity, any gynecological condition, and index of multiple deprivation.
kStratified analyses performed after the interaction term between use of HRT and smoking gave P < .20.
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founding on the effect estimates, we calculated the E value,
which provides evidence that our results regarding previous HRT
use were not substantially influenced by residual confounding,
whereas results for current HRT use seemed to have been
influenced by residual confounding. Our plan to investigate the
role of routes of administration of HRT (oral, transdermal,
subcutaneous, intramuscular, or local intrauterine) was not
possible, because this information was not consistently recorded
in the database. In the context of coronary heart disease and
overall mortality, the timing hypothesis has been highlighted,
indicating that the timing of use of HRT in proximity to the
timing of onset of menopause seems to be critical and thus
provides a window of opportunity for primary prevention.24
However, although to our knowledge no previous study has
evaluated this hypothesis in the context of asthma, we did not
have the required data to define this aspect in the current study.
Of the 7 studies25-31 identified in our previous systematic re-
view6 to have investigated the association between HRT and
clinical outcomes of asthma in perimenopausal and post-
menopausal women, 4 were cross-sectional studies,25-28 whereas 3
were very small retrospective case-control studies.29-31 The design
of the studies, which was graded as weak in that systematic review,
does not allow establishment of temporality in the association
between HRT and clinical outcomes of asthma; thus the previous
studies are of poorer quality and not comparable with the current
study.6 Assessment of HRT and study outcomes, based on self-
report in most of the previous studies, exposed the studies togreater risk of ascertainment bias. To date, the current study, with
long-term follow-up and longitudinal design, is the most robustly
undertaken to address the question of the role of HRT in clinical
outcomes of asthma in perimenopausal and postmenopausal
women. Our results indicate that use of HRT and subtypes,
particularly previous rather than current use, was associated with
an increased risk of severe asthma exacerbation, both in peri- and
postmenopausal women. Furthermore, we found that long-term
rather than short-term HRT use was associated with an
increased risk of severe asthma exacerbation. The increased risk of
HRT use on severe asthma exacerbation was greatest in women
with BMI<25 kg/m2 and least in those with BMI30 kg/m2, as
well greater in ex-/current smokers than in nonsmokers.
The proposed impact of HRT on asthma is complex, as HRT
has been shown to exert both anti-inflammatory and proin-
flammatory effects on innate32,33 and adaptive immunity.34 The
role of HRT in inflammation is attributed primarily to the effects
of estrogen through the activities of estrogen receptors (ERs), ERa
and ERb, both of which are expressed on immune cells, but are
also present in the lung; they regulate cells and pathways in both
the innate and adaptive immune system.33 Monocytes in pre-
menopausal women are reported to have lower amounts of ERa
RNA than monocytes isolated from males and postmenopausal
women, suggesting that higher estradiol levels correlate with
reduced ERa expression.35 ERa and ERbRNA levels however did
not differ in male and female B and T lymphocytes, or in lym-
phocytes of peri- and postmenopausal women.35 A preponderance
of one or other ER is suggested to modify the effects of estrogen,36
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asthmatic and healthy airways.36 However, the molecular mech-
anisms that may result in sex differences in ER expression in
particular immune cells remain to be defined. Further mechanistic
studies are required to better understand the biology underpinning
the influence of HRT on clinical outcomes in perimenopausal and
postmenopausal women with established asthma and also to un-
derstand whether the route of steroid replacement delivery plays a
role. Overall, our results indicate that previous and long-term, but
not current, HRT use are crucial, perhaps indicating that with-
drawal of HRT use among those with long-term exposures may
constitute a preventative measure for severe asthma exacerbations.
It is, however, unclear whether the increased number of exacer-
bations given previous or long-term HRT use is a one-off risk,
possibly coincident with a sudden decline in estrogen, or repre-
sents a continuing effect.
The interaction between HRT and BMI in relation to asthma
has been hypothesized to perhaps be an indication of a common
pathway for the impact of HRT and BMI on asthma.36 Although
BMI is closely linked to insulin resistance,37,38 there is evidence
that insulin resistance is also closely involved in local estrogen
production.39,40 In womenwith low BMI, insulin resistance is low
and this may portend a proinflammatory effect of HRT, but in
women with high BMI, there appears a counterbalance between
estrogen and insulin resistance, whereby the effect of HRT on
asthma may be minimal.41 These propositions may explain our
current observations in which the impact of HRT on risk of severe
asthma exacerbation was greatest for lean women and lowest for
heavier women. A possible explanation for our findingsmay be that
low levels of estrogen (and symptoms thereof) at onset of meno-
pause prompt the use of HRT. During the period of use of HRT,
the woman is somewhat protected from asthma exacerbations.
However, when discontinuing treatment, which is recommended
after 1 to 5 years, and being nonobese, the levels of estrogen drop,
potentially increasing women’s risk of asthma exacerbations.
Concerning the differential effect of HRT on severe asthma
exacerbation between nonsmokers and smokers, the potential
underlying mechanism is unclear, and thus requires further studies
for confirmation as well as mechanistic investigations to highlight
the biological pathways through which these results are tenable.CONCLUSIONS
Our results demonstrate that the use of HRT and subtypes by
perimenopausal and postmenopausal women with established
asthma, particularly previous HRT use and long-term use but
not current use, is associated with an increased risk of severe
asthma exacerbation. Lean women and smokers were at greatest
risk than heavier women and smokers, respectively. There is a
need to confirm the current findings by further longitudinal
studies. In such studies, identification of new users of HRT will
enhance establishment of a casual relationship between HRT and
clinical outcomes of asthma. Furthermore, mechanistic studies
investigating the biologic processes underlying the impact of
HRT on clinical outcomes of asthma in perimenopausal and
postmenopausal women are required.
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